Tough times are ahead for pharma majors as research pipelines around the globe are drying up. The latest victim is Glenmark Pharma. Glenmark Pharmaceutical on Friday announced its partner Elli Lilly's decision to suspend further clinical development for its Osteoarthritis pain molecule, has clearly left a big hole in its R&D pipeline.
